The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives ...
Vertex is awaiting the potential approval of Trikafta in many other countries and in pediatric patients not yet approved for the drug, but we think the eligible patient population for Vertex’s four ...
Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...
Vertex is awaiting the potential approval of Trikafta in many other countries and in pediatric patients not yet approved for the drug, but we think the eligible patient population for Vertex’s four ...
(RTTNews) - Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of ...
Vertex Pharmaceuticals' top line has grown significantly over the years thanks to the approval of Trikafta in 2019. The company recently obtained approval for a gene therapy treatment, Casgevy. Strong ...
Vertex Pharmaceuticals (NASDAQ: VRTX) transformed the world of cystic fibrosis (CF) treatment when it launched its first product for the disease 12 years ago. Since then, it's built a CF treatment ...
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s ...
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...
WHITE OAK, MD - JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. This story was originally published on BioPharma Dive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback